Abstract
Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to one of long-term management, but treatment success is challenged with poor medication adherence. Many risk factors associated with poor adherence can be ameliorated by close monitoring, dose modification, and supportive care. Controlling risk factors for poor adherence in combination with patient education that includes direct communication between the health care team and the patient are essential components for maximizing the benefits of TKI therapy.
Copyright © 2012 Wiley Periodicals, Inc.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / economics
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Drug Costs
-
Drug Monitoring
-
Health Care Costs
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myeloid, Chronic-Phase / drug therapy*
-
Leukemia, Myeloid, Chronic-Phase / economics
-
Medication Adherence*
-
Patient Education as Topic
-
Piperazines / administration & dosage
-
Piperazines / adverse effects
-
Piperazines / economics
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / economics
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / economics
-
Pyrimidines / therapeutic use
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases